Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

The Internist’s Approach to Leveraging Continuous Glucose Monitoring in Diabetes
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Physician Assistants: maximum of 1.0 hour of AAPA Category 1 CME credit
Released: May 27, 2022 Expiration: May 26, 2023
Start Activity
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Abbott Diabetes Care Inc.
Martin J. Abrahamson, MD, FACP
Program Director
Leslie Eiland, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the main components and key metrics of available CGM devices
  • Discuss the benefits of CGM metrics in optimizing glycemic control and reducing hypoglycemia risk in patients with T1D and T2D
  • Identify patient qualities that would make them good candidates for CGM
  • Identify strategies to overcome patient and HCP barriers to CGM

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Martin J. Abrahamson MD, FACP, has disclosed that he has received consultant fees from Novo Nordisk and WebMD Health Services.

Faculty

Leslie Eiland, MD

Assistant Professor
Division of Diabetes, Endocrinology & Metabolism
University of Nebraska Medical Center
Omaha, Nebraska

Leslie Eiland, MD, has disclosed that she has received advisor fees from Cecelia Health, Provention Bio, Roche, and Sanofi.

Staff

Robin Black, PharmD, BCACP

Scientific Director

Robin Black, PharmD, BCACP, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, NP, has no relevant conflicts of interest to report.
Tracy Piparo, PA-C

Department of Palliative Medicine
RJWBarnabas
New Brunswick, New Jersey

Tracey Piparo, PA-C, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended to meet the educational needs of internists and advanced practice professionals (nurse practitioners and physician associates/physician assistants) as well as other HCPs who care for patients with diabetes.

Goal

The goal of this activity is to provide internists with the necessary knowledge and competence to initiate and optimally use CGM devices in appropriate patients with diabetes, with a key focus on developing strategies to overcome barriers to fully integrating CGM into daily practice.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for maximum of 1.0 hour of AAPA Category I CME credit. Approval is valid until May 26, 2023. PAs should only claim commensurate with the extent of their participation.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 27, 2022, through May 26, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

The Internist’s Approach to Leveraging Continuous Glucose Monitoring in Diabetes
  • CME
  • CE

Loading...
In this interactive on-demand program, expert faculty provide insights on the initiation and optimal use of CGM devices in patients with diabetes.
Martin J. Abrahamson, MD, FACP
Program Director
Leslie Eiland, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Physician Assistants: maximum of 1.0 hour of AAPA Category 1 CME credit
Released: May 27, 2022 Expiration: May 26, 2023

Related Content

Concise microlearning module featuring expert insight on the cardiorenal benefits of finerenone in T2D and CKD from Clinical Care Options (CCO)

Vivian A. Fonseca, MD, FRCP
Program Director
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: August 4, 2022 Expired: August 3, 2023

Commentary on clinical use of SGLT2 inhibitors in diabetic kidney disease, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: July 21, 2022

Concise microlearning module featuring expert insight on the cardiorenal benefits of SGLT2 inhibitors in T2D from Clinical Care Options (CCO)

Jennifer B. Green, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: July 12, 2022 Expired: July 11, 2023

Unlocked downloadable slides featuring an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: July 12, 2022
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Abbott Diabetes Care Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings